Response of sarcomas of bone and of soft tissue to neutron beam therapy.
A total of 51 patients were treated at Fermilab for sarcoma of bone (25 patients) and soft tissue (26 patients). Neutrons were delivered in twice weekly fractions over 6-7 weeks to total doses between 18 and 26 Gy. Long-term local control (greater than 2 years) was achieved in 24 patients (47%). Overall local control rates were 44% in the bone sarcomas and 50% in the soft tissue tumors. Chondrosarcoma appeared relatively more responsive with 9 out of 16 (56%) controlled, compared to osteogenic sarcoma with 2 out of 9 (22%) controlled. Among the soft tissue tumors, liposarcoma (5/7 controlled) and neurogenic sarcoma (3/3 controlled) appear to be more responsive than other tumors. The overall survival rate was 40% in the entire series. These results are comparable with international experience in neutron therapy of sarcomas of bone and soft tissues. Out of 263 soft tissue sarcomas treated with neutrons only to full dosage throughout the world, 152 (58%) were locally controlled. Similarly out of 74 sarcomas of bone so treated, 44 (60%) were controlled.
D001859:Bone Neoplasms / Q000532:radiotherapy*; D002813:Chondrosarcoma / Q000532:radiotherapy; D004307:Dose-Response Relationship, Radiation; D005354:Fibrosarcoma / Q000532:radiotherapy; D006801:Humans; D007890:Leiomyosarcoma / Q000532:radiotherapy; D008080:Liposarcoma / Q000532:radiotherapy; D009455:Neurofibroma / Q000532:radiotherapy; D009502:Neutrons; D012516:Osteosarcoma / Q000532:radiotherapy; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D012509:Sarcoma / Q000532:radiotherapy*; D012983:Soft Tissue Neoplasms / Q000532:radiotherapy*